Translated material
Russia wants to start testing a vaccine against breast cancer
The Nikolai Gamaleya Center for Epidemiology and Microbiology intends to begin testing a vaccine against breast cancer, as well as vaccines against kidney and pancreatic cancer, by the end of the year. The director of the center, Alexander Ginzburg, told TASS that the condition for the success of scientific developments is the amount of funding.
Scientists plan to create models of cancer diseases in order to then develop personalized mRNA vaccines for them, said the head of the research center.
If the amount of funding “will be the same as we agreed,” the center’s specialists this year will begin making “oncology disease models” that will make it possible to create vaccines against small cell lung cancer. “As you know, this is the most common human cancer with the highest mortality and severe outcomes,” explained Gunzburg.
Beef fat on the face TikTok people have fallen in love with a homemade cream based on “natural ingredients.” Dermatologists warn it could be dangerous
Internet and memes 13 min read
Depending on funding, the center will additionally launch two or three lines of testing animal models of cancer. “So that at the end of this year or the beginning of next year we can already count on the fact that our colleagues from oncology centers will be able to begin testing oncology vaccines on patients with these oncological diseases,” said the head of the scientific institution.
The director of the Gamaleya Center told TASS that neural networks will be used for calculations when creating personalized cancer vaccines. To train AI, scientists intend to create a database of genetic sequences of 40-50 thousand tumors.
“I recommend that those who are saying goodbye to life be capricious” How cancer psychologists support dying people and grieving relatives Society 7 minute read
In September, the center plans to begin human studies of an oncology vaccine against melanoma. “Everything has been worked out with melanoma,” assured Gunzburg. According to him, preclinical studies of the vaccine showed that the drug suppresses tumor development.
The chief freelance oncologist of the Ministry of Health, Andrei Kaprin, said in October that preclinical trials of a drug for melanoma have already been completed.
At the end of December, it became known that sales of dostarlimab, a drug that has shown 100% effectiveness in the treatment of colorectal cancer, have been approved in the United States. The US Food and Drug Administration has granted the drug Breakthrough Therapeutic Designation.
In order not to miss the main materials of “Cold”, subscribe to our social networks!
